View
An End-to-end Approach to Precision Medicine
FoundationOne CDx was recently approved to identify mutations that lead to MET exon 14 skipping in advanced non-small cell lung cancer (NSCLC) and match patients with a new targeted therapy, which was approved in parallel. Learn more about how this approval demonstrates the power of cancer precision medicine in action and the role that comprehensive genomic profiling plays.
From the Foundation Forward Blog
-
October 15, 2020
A New Collaboration to Build the Future of Cancer Care
-
September 14, 2020
Helping More Patients Benefit from Precision Cancer Care with A Portfolio of Genomic Testing Options | Foundation Medicine
-
August 27, 2020
A New Decade of Possibility for Precision Oncology | Foundation Medicine
-
August 05, 2020
Informing the Patient Journey with Deep Genomic Insights
-
May 18, 2020
An End-To-End Approach To Precision Medicine: MET Exon 14 Skipping Mutations In Non-Small Cell Lung Cancer (NSCLC) | Foundation Medicine